Department of Life Sciences, School of Science, University of Management and Technology, C-II, Johar Town, Lahore, Pakistan.
J Infect Public Health. 2020 Jan;13(1):149-150. doi: 10.1016/j.jiph.2019.06.004. Epub 2019 Jun 21.
Hepatitis C virus (HCV) is the leading cause of morbidity and mortality worldwide. It causes both chronic and acute infections and it has been estimated that about 80% of HCV infected patients develop chronic HCV infection of which 15-30% develop liver complications specifically liver cirrhosis and hepatocellualar carcinoma (HCC). Interferon therapy was previously used standard of care therapy associated with poor efficacy in major proportion of HCV infected population whereas, the recent development of interferon-free therapy or direct-acting antiviral (DAA) drugs are able to achieve sustained virological response (SVR) in 95% of patients. These new drugs are still not properly explored and currently there is minimal clinical experience regarding an efficacious treatment option suitable for triple infection i.e, Hepatitis B virus (HBV), HCV, and Hepatitis E virus (HEV). Here, we suggest well-tolerated sofsobuvir-based treatment regimen in patient infected with HBV, HCV, and HEV. Twelve weeks long treatment with sofsobuvir, daclatasvir, ribavirin, and tenofovir resulted in sustained virological response (SVR) and cleared HBV, HCV, and HEV in diabetic and asthmatic patient.
丙型肝炎病毒 (HCV) 是全球发病率和死亡率的主要原因。它会引起慢性和急性感染，据估计，大约 80%的 HCV 感染患者会发展为慢性 HCV 感染，其中 15-30%会发展为肝脏并发症，特别是肝硬化和肝细胞癌 (HCC)。干扰素治疗曾是标准的护理治疗方法，但在 HCV 感染人群中，其疗效不佳，而最近开发的无干扰素治疗或直接作用抗病毒 (DAA) 药物能够使 95%的患者达到持续病毒学应答 (SVR)。这些新药尚未得到充分探索，目前对于适合三感染（即乙型肝炎病毒 (HBV)、丙型肝炎病毒和戊型肝炎病毒 (HEV)）的有效治疗选择，临床经验很少。在这里，我们建议对感染了 HBV、HCV 和 HEV 的患者使用耐受性良好的索非布韦为基础的治疗方案。12 周的索非布韦、达卡他韦、利巴韦林和替诺福韦治疗使一位糖尿病和哮喘患者的病毒学应答持续 (SVR)，并清除了 HBV、HCV 和 HEV。
